H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

Learn more about whether BioMarin Pharmaceutical Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ ...

In a report released on November 29, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report).

The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks ...

The market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for ...

I hope you had a wonderful Thanksgiving! As I expected, the stock market was relatively quiet as folks headed out early for the holiday. But although trading was light, stocks still marched higher.

Not knowing where these conversations will go, the show "allows us to enjoy the technology ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...